Next Article in Journal
Radiation Treatment Waiting Times for Breast Cancer Patients in Manitoba, 2001 and 2005
Previous Article in Journal
131I–Tositumomab in Lymphoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue 5
10.3747/co.v16i5.510
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers

by
J. Lemieux
1,2,*,
M. Clemons
3,
L. Provencher
2,
S. Dent
4,
J. Latreille
5,
J. Mackey
6,
K. I. Pritchard
7,
D. Rayson
8,
Sh. Verma
4,
Su. Verma
7,
B. Wang
9 and
S. Chia
10
1
Unité de recherche en santé des populations, Centre de Recherche du Centre Hospitalier affilié universitaire de Québec, Quebec City, QC, Canada
2
Hôpital du Saint-Sacrement, Quebec City, QC, Canada
3
Princess Margaret Hospital, Toronto, ON, Canada
4
Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
5
Centre Intégré de cancérologie de la Montérégie and Réseau Cancer Montérégie, Longueuil, QC, Canada
6
Cross Cancer Institute, Edmonton, AB, Canada
7
Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
8
Atlantic Clinical Cancer Research Unit and QEII Health Sciences Centre, Halifax, NS, Canada
9
Remedy Communications Limited, Toronto, ON, Canada
10
British Columbia Cancer Agency–Vancouver Centre, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(5), 48-57; https://doi.org/10.3747/co.v16i5.510
Submission received: 3 June 2009 / Revised: 9 July 2009 / Accepted: 11 August 2009 / Published: 1 September 2009

Abstract

Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with early-stage breast cancer positive for the human epidermal growth factor receptor 2 (her2), questions have been raised about the use of trastuzumab in the neoadjuvant setting. The present paper reviews the currently available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other her2-targeted agents in the neoadjuvant setting. The panel focussed on (1) the use of trastuzumab and other her2-targeted agents as neoadjuvant therapy in primary operable, locally advanced, and inflammatory breast cancer; and (2) possible choices of chemotherapeutic regimens with trastuzumab. The suggestions described here will continue to evolve as data from current and future trials with trastuzumab and other her2-targeted agents emerge.
Keywords: neoadjuvant; breast cancer; her2-targeted therapy; trastuzumab neoadjuvant; breast cancer; her2-targeted therapy; trastuzumab

Share and Cite

MDPI and ACS Style

Lemieux, J.; Clemons, M.; Provencher, L.; Dent, S.; Latreille, J.; Mackey, J.; Pritchard, K.I.; Rayson, D.; Verma, S.; Verma, S.; et al. The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers. Curr. Oncol. 2009, 16, 48-57. https://doi.org/10.3747/co.v16i5.510

AMA Style

Lemieux J, Clemons M, Provencher L, Dent S, Latreille J, Mackey J, Pritchard KI, Rayson D, Verma S, Verma S, et al. The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers. Current Oncology. 2009; 16(5):48-57. https://doi.org/10.3747/co.v16i5.510

Chicago/Turabian Style

Lemieux, J., M. Clemons, L. Provencher, S. Dent, J. Latreille, J. Mackey, K. I. Pritchard, D. Rayson, Sh. Verma, Su. Verma, and et al. 2009. "The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers" Current Oncology 16, no. 5: 48-57. https://doi.org/10.3747/co.v16i5.510

APA Style

Lemieux, J., Clemons, M., Provencher, L., Dent, S., Latreille, J., Mackey, J., Pritchard, K. I., Rayson, D., Verma, S., Verma, S., Wang, B., & Chia, S. (2009). The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers. Current Oncology, 16(5), 48-57. https://doi.org/10.3747/co.v16i5.510

Article Metrics

Back to TopTop